EU should take a lead in enforcing the corporate social responsibility of gene therapy manufacturers. Viewpoint of Prof. Michel Goldman
After decades of research – much of it funded by the public – gene therapy is a reality. Now high costs are blocking patient access. Prices should be constrained Source Science Business Gene therapy is providing unprecedented hope for growing numbers of patients and families. This game changer in medicine restores vision in babies born